Since then, supply has returned thanks to Lilly's investments in manufacturing and a move to also offer Zepbound, previously ...

VKTX is likely to have headed into Q3 earnings with no product revenue, pipeline updates in focus and widening loss forecasts testing investor patience.

Viking Therapeutics (VKTX) is back in the spotlight with investors eyeing the company’s advancing clinical pipeline, including its VK2735 obesity drug now in phase 3 trials. Expectations are also ...

Viking is developing VK2735, its dual GIP/GLP-1 receptor agonist, in injectable form -- like current marketed weight ...

Eli Lilly holds the lead position in the weight management market right now. But Viking Therapeutics is working on a ...

Viking Therapeutics shows promise with their VK2735 drug demonstrating significant weight loss in Phase 2 trials. Despite strong data, Viking faces intense competition and strategic challenges in a ...

It has been a little more than two months since my last Viking Therapeutics, Inc. (NASDAQ:VKTX) article, where I highlighted their promising pipeline for obesity, NASH/MASH, and X-ALD programs that ...

River cruise operator Viking reported first-quarter results on Wednesday morning. The stock sank on the news. Viking's revenue rose 14% -- less than traditional cruise line companies -- but there are ...

Pfizer has agreed to acquire Metsera, a company specializing in weight-loss medications, for $47.50 per share in cash, along ...

Viking’s newly announced 2027-28 deployment includes six ships operating winter itineraries in Europe. Nearly half of the ...

CINCINNATI, Aug. 5, 2025 /PRNewswire/ -- Viking Partners, a private real estate investment firm, closed on a $50.4 million acquisition of a 409,000-square-foot portfolio of small-bay industrial assets ...